Reporter brief
COVID-FIS: A Phase 2 Placebo-Controlled Pilot Study in COVID-19 of Fisetin to Alleviate Dysfunction and Excessive Inflammatory Response in Older Adults in Nursing Homes
What happened
Trial registry update: TERMINATED. Results are posted in the registry; assessment pending.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- No results are reported in the abstract, making it impossible to assess whether the intervention actually worked or produced clinical benefit in this population
- The study design and phase do not establish whether any observed effect would generalize beyond nursing home residents or persist beyond the acute COVID-19 episode
- The mechanism by which fisetin might work in acute COVID-19 infection is not addressed; senolytic effects on chronic age-related pathology may differ from effects during active viral infection
Study design and sample
Rct; Human.
Older adults in nursing homes with COVID-19
- Design
- Rct
- Sample
- —
- Journal
- Mayo Clinic
- Published
- Aug 26, 2025
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.